Zacks Investment Research upgraded shares of Veru (NASDAQ:VERU) from a sell rating to a buy rating in a report published on Wednesday morning. Zacks Investment Research currently has $1.50 price objective on the stock.
According to Zacks, “Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL. “
A number of other research analysts have also recently commented on VERU. Dawson James reiterated a buy rating on shares of Veru in a research report on Monday, June 25th. ValuEngine upgraded shares of Veru from a hold rating to a buy rating in a research report on Wednesday, August 15th. HC Wainwright reissued a buy rating and set a $5.00 price objective on shares of Veru in a research note on Wednesday, August 15th. Finally, Maxim Group began coverage on Veru in a research note on Tuesday, July 3rd. They set a buy rating for the company. Five analysts have rated the stock with a buy rating, The stock presently has a consensus rating of Buy and an average target price of $5.50.
Veru (NASDAQ:VERU) last issued its quarterly earnings results on Tuesday, August 14th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.07). Veru had a negative net margin of 130.26% and a negative return on equity of 38.09%. The business had revenue of $5.50 million for the quarter, compared to the consensus estimate of $5.20 million. Equities research analysts forecast that Veru will post -0.32 earnings per share for the current year.
An institutional investor recently bought a new position in Veru stock. ACG Wealth acquired a new stake in shares of Veru Inc (NASDAQ:VERU) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 77,000 shares of the company’s stock, valued at approximately $156,000. ACG Wealth owned 0.14% of Veru as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 5.20% of the company’s stock.
Veru Company Profile
Veru Inc operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
Featured Story: Understanding Price to Earnings Ratio (PE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.